Role of Statins in Glucose Homeostasis and Insulin Resistance

Chanukya Dahagam, Virginia S. Hahn, Aditya Goud, Jason D’Souza, Abdelhai Abdelqader, Roger S Blumenthal, Seth Martin

Research output: Contribution to journalReview article

Abstract

Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.

Original languageEnglish (US)
Article number40
JournalCurrent Cardiovascular Risk Reports
Volume10
Issue number12
DOIs
StatePublished - Dec 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Insulin Resistance
Homeostasis
Glucose
Cardiovascular Diseases
Guidelines
American Heart Association
Primary Prevention
Secondary Prevention
Cardiology
Counseling
Weight Loss
Decision Making
Therapeutics
Cholesterol
Incidence
Serum

Keywords

  • Cardiovascular disease
  • Cholesterol
  • Diabetes
  • Hyperglycemia
  • Insulin resistance
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Role of Statins in Glucose Homeostasis and Insulin Resistance. / Dahagam, Chanukya; Hahn, Virginia S.; Goud, Aditya; D’Souza, Jason; Abdelqader, Abdelhai; Blumenthal, Roger S; Martin, Seth.

In: Current Cardiovascular Risk Reports, Vol. 10, No. 12, 40, 01.12.2016.

Research output: Contribution to journalReview article

Dahagam, Chanukya ; Hahn, Virginia S. ; Goud, Aditya ; D’Souza, Jason ; Abdelqader, Abdelhai ; Blumenthal, Roger S ; Martin, Seth. / Role of Statins in Glucose Homeostasis and Insulin Resistance. In: Current Cardiovascular Risk Reports. 2016 ; Vol. 10, No. 12.
@article{1e3e6a7f0b764a9383914b893dbd45ec,
title = "Role of Statins in Glucose Homeostasis and Insulin Resistance",
abstract = "Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.",
keywords = "Cardiovascular disease, Cholesterol, Diabetes, Hyperglycemia, Insulin resistance, Statins",
author = "Chanukya Dahagam and Hahn, {Virginia S.} and Aditya Goud and Jason D’Souza and Abdelhai Abdelqader and Blumenthal, {Roger S} and Seth Martin",
year = "2016",
month = "12",
day = "1",
doi = "10.1007/s12170-016-0523-4",
language = "English (US)",
volume = "10",
journal = "Current Cardiovascular Risk Reports",
issn = "1932-9520",
publisher = "Current Medicine Group",
number = "12",

}

TY - JOUR

T1 - Role of Statins in Glucose Homeostasis and Insulin Resistance

AU - Dahagam, Chanukya

AU - Hahn, Virginia S.

AU - Goud, Aditya

AU - D’Souza, Jason

AU - Abdelqader, Abdelhai

AU - Blumenthal, Roger S

AU - Martin, Seth

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.

AB - Statins are widely used for primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), and, under the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol treatment guidelines, more individuals are eligible for statin therapy. In this review, we summarize evidence for a mild increase in serum glucose and increased incidence of diabetes associated with statins, the hypothesized mechanisms by which statins may impair glucose homeostasis, the risk of diabetes associated with particular statins, and the net effect on ASCVD risk. As emphasized by the ACC/AHA guideline group and other experts, the risk-reducing benefits of statin therapy generally outweigh the mild rise in glucose levels or new diagnoses of diabetes. As such, an appropriate balancing of benefits and risks is critical in clinical practice as clinicians engage patients in shared decision making. Moreover, when discussing statins and risk of diabetes, this is a prime opportunity for clinicians to provide further counseling on the central importance of weight loss and adhering to a healthy lifestyle in glucose homeostasis and diabetes prevention.

KW - Cardiovascular disease

KW - Cholesterol

KW - Diabetes

KW - Hyperglycemia

KW - Insulin resistance

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84992390299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992390299&partnerID=8YFLogxK

U2 - 10.1007/s12170-016-0523-4

DO - 10.1007/s12170-016-0523-4

M3 - Review article

VL - 10

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

SN - 1932-9520

IS - 12

M1 - 40

ER -